Drugs / Autologous bone marrow-derived mesenchymal stem cells

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT02477540 Dec 2019 → Jun 2020 limb ischemia Pharmicell Co., Ltd. Withdrawn No outcome recorded
Phase 1 NCT03838250 Jun 2019 → Mar 2021 alcoholic liver cirrhosis Pharmicell Co., Ltd. Unknown No outcome recorded
Phase 1 NCT03361631 Jun → Jul 2018 erectile dysfunction, type 1 diabetes mellitus Central Hospital, Nancy, France Unknown No outcome recorded
Phase 1 NCT01162915 Jul 2010 → May 2014 spinal cord injury TCA Cellular Therapy Suspended No outcome recorded
Phase 1 NCT01751282 Jun 2010 → Jun 2015 chronic ulcer of skin Roger Williams Medical Center Terminated No outcome recorded
Phase 22 trials
Phase 2 NCT01461720 Mar 2012 → Dec 2015 middle cerebral artery infarction National University of Malaysia Unknown No outcome recorded
Phase 2 NCT01459640 Mar 2011 → Mar 2014 osteoarthritis National University of Malaysia Unknown No outcome recorded
Phase not applicable1 trial
NCT04735185 Sep → Nov 2025 chronic pain syndrome, lumbar disk degenerative disorder Johns Hopkins University Withdrawn No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Autologous bone marrow-derived mesenchymal stem cells “The purpose of this study is to determine the effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in the treatment of non-healing wounds.” NCT01751282
5

“intradiscal injection of autologous bone marrow-derived mesenchymal stem cells from bone marrow aspirate of the posterior ilium” NCT04735185

NCT01461720

NCT01162915

NCT03361631

NCT01459640

Known as Cellgram ClinicalTrials.gov intervention name — accepted as the source's own label NCT03838250
Known as Cellgram-CLI ClinicalTrials.gov intervention name — accepted as the source's own label NCT02477540
Known as MSCs “The purpose of this study is to determine the effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in the treatment of non-healing wounds.” NCT01751282
Modality Cell therapy “Infusion of autologous bone marrow-derived mesenchymal stem cells.” NCT01162915
Route Intrathecal Intrathecal infusion of a single dose of ex vivo expanded MSC.” NCT01162915